BioCentury
ARTICLE | Clinical News

STM 434: Preliminary Phase I data

May 30, 2016 7:00 AM UTC

Preliminary data from 22 patients with advanced solid tumors in a 3-part, open-label, dose-escalation, U.S. Phase I trial showed that 0.25, 0.5, 0.75 and 1 mg/kg doses of IV STM 434 every 2-4 weeks le...